Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)

Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) Charles G Drake, David Quinn, Robert Dreicer, Emmanuel Antonarakis, Neal Shore, John Corman, Raoul Concepcion, Christopher Pieczonka, Dwayne Campogan, Li-Qun Fan, Nancy Chang, Nadeem Sheikh, Daniel Petrylak